Literature DB >> 34034998

CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.

Songtao Zhang1, Qiujie Yan2, Song Wei3, Xiaobo Feng4, Miaomiao Xue2, Lina Liu2, Jili Cui2, Yuanyuan Zhang5.   

Abstract

OBJECTIVES: This study aimed to evaluate the expression of chemokine-like factor superfamily 6 (CMTM6) and programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) in oral squamous cell carcinoma (OSCC) and to further explore its clinical significance in OSCC. STUDY
DESIGN: Samples of 44 OSCC and paracancerous tissues were investigated. We estimated the expression of the 3 proteins by immunohistochemistry and further detected mRNA expression by quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: Immunohistochemistry results demonstrated that the positive expression of CMTM6 and PD-1/PD-L1 in OSCC tissues was significantly higher than that in paracancerous tissues. Statistical significance was found between the 2 groups (all P < .05). Moreover, PD-L1 expression was related to OSCC clinical stage and lymph node metastasis (P < .05). The qRT-PCR results confirmed that the relative expression of CMTM6 and PD-1/PD-L1 mRNA in OSCC tissues was significantly higher than that in paracancerous tissues (all P < .05), and Spearman rank correlation showed that there was a significant relationship between mRNA and protein expression (all P < .05).
CONCLUSIONS: CMTM6 and PD-1/PD-L1 were upregulated in OSCC, and CMTM6 may play a synergistic role with PD-1/PD-L1 in the immune pathway. Therefore, we believe that CMTM6 and PD-1/PD-L1 will become checkpoints for immunotherapy of OSCC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34034998     DOI: 10.1016/j.oooo.2021.02.019

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  5 in total

1.  DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Ling-Ling Fu; Ming Yan; Min-Xian Ma; Yi Luo; Min Shao; Martin Gosau; Reinhard E Friedrich; Tobias Vollkommer; Hong-Chao Feng; Ralf Smeets
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.

Authors:  Vinícius Gonçalves de Souza; Damilys Joelly Souza Santos; Ana Gabriela Silva; Rosy Iara Maciel de Azambuja Ribeiro; Adriano Mota Loyola; Sérgio Vitorino Cardoso; Carla Silva Siqueira Miranda; Ludimila Paula Vaz Cardoso
Journal:  J Appl Oral Sci       Date:  2022-02-21       Impact factor: 2.698

3.  Beyond PD-L1-Identification of Further Potential Therapeutic Targets in Oral Cancer.

Authors:  Manuel Weber; Rainer Lutz; Manuel Olmos; Jacek Glajzer; Christoph Baran; Christopher-Philipp Nobis; Tobias Möst; Markus Eckstein; Marco Kesting; Jutta Ries
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

Review 4.  CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review.

Authors:  Jie Li; Xiaozi Wang; Xiaoning Wang; Yan Liu; Na Zheng; Pengwei Xu; Xianghong Zhang; Liying Xue
Journal:  Cancer Manag Res       Date:  2022-04-26       Impact factor: 3.602

Review 5.  CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.

Authors:  Tong Zhang; Haixiang Yu; Xiangpeng Dai; Xiaoling Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.